QSAR study on the antinociceptive activity of some morphinans

Chemical Biology and Drug Design

Volumn 70, Issue 1, 2007, Pages 53-64

  Ramírez Galicia, Guillermo ^a   Garduño Juárez, Ramón ^a   Hemmateenejad, Bahram ^b   Deeb, Omar ^c   Deciga Campos, Myrna ^d   Moctezuma Eugenio, Juan Carlos ^e  

^a INSTITUTO DE CIENCIAS FÍSICAS   (Mexico)

^b SHIRAZ UNIVERSITY   (Iran)

^c AL QUDS UNIVERSITY   (Palestine)

^d UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^e INSTITUTO NACIONAL DE ASTROFÍSICA   (Mexico)

Author keywords

Antinociceptive activity; Cheminformatics; Hot Plate; Morphinan derivatives; Natural products; Quantitative structure activity relationship; Structure based drug design

Indexed keywords

MORPHINAN DERIVATIVE;

ARTICLE; ARTIFICIAL NEURAL NETWORK; DRUG ACTIVITY; DRUG STRUCTURE; MOUSE; MULTIPLE REGRESSION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; UNITED STATES;

ANALGESICS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MORPHINANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 34447308558     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00530.x     Document Type: Article

References (46)

1. Casy A.F., Parfitt R.T. (1986) Opioid Analgesics - Chemistry and Receptors. New York : Plenum Press.
2. Lord J.A.H., Waterfield J.A., Hughes J., Kosterlitz J.H.W. (1977) Endogenous opioids: multiple agonists and receptors. Nature 267 : 495 499.
3. Alexander S.P.H., Mathie A., Peters J.A. (2001) TiPS nomenclature supplement 2001. Trends Pharm Sci 22-S1 : 1.
4. Jiang Q., Takemori A.E., Sultana M., Portoghese P.S., Bowen W.D., Mosberg H.I., Porecca F. (1991) Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther 257 : 1069 1075.
5. Wolozin B.L., Pasternak G.W. (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci 78 : 6181 6185.
6. Pert C.B., Snyder S.H. (1973) Opiate receptor: demonstration in nervous tissue. Science 179 : 1011 1014.
7. Law P.Y., Wong Y.H., Loh H.H. (2000) Molecular mechanism and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40 : 389 430.
8. Hyytia P. (1993) Involvement of mu-receptor in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav 45 : 697 701.
9. Schiller P.W., Fundytus M.E., Merovitz L., Weltrowska G., Nguyen T.M., Lemieux C., Chung N.N., Coderre T.J. (1999) The opioid mu agonist/delta agonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 42 : 3520 3526.
10. Millan M.J. (1990) Kappa-opioid receptor and analgesia. Trends Pharmacol Sci 11 : 70 76.
11. Coop A., MacKerell A.D. Jr. (2002) The future of opioid analgesics. Am J Pharm Educ 66 : 153 156.
12. Hansch C., Leo A. (1995). In : Heller S.R., editor. Exploring QSAR: Fundamental and Application in Chemistry and Biology. Washington, DC : American Chemical Society 6 : 161 222.
13. Krogsgaard-Larsen P., Liljefors T., Madsen U. (2002) Textbook of Drug Design and Discovery. London : Taylor and Francis.
14. Todeschini R., Consonni V. (2000) Handbook of Molecular Descriptors. Weinheim, Germany : Wiley-VCH.
15. Karelson M. (2000) Molecular Descriptors in QSAR/QSPR. Wiley-Interscience, New York, USA.
16. Li W., Tang Y., Zheng Y.-L., Qiu Z.-B. (2006) Molecular modeling and 3D-QSAR studies of indolmorphinan derivatives as kappa opioid antagonists. Bioorg Med Chem 14 : 601 610.
17. Zhang A., Xiong W., Bidlack J.M., Hilbert J.E., Knapp B.I., Wentland M.P., Neumeyer J.L. (2004) 10-ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and mu opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptor. J Med Chem 47 : 165 174.
18. Gómez-Jeria J.S., Gerli-Candia L.A., Hurtado S.M. (2004) A structure-affinity study of the opioid binding of some 3-susbtituted morphinans. J Chil Chem Soc 49 : 307 312.
19. Xu L., Zhang W.J. (2001) Comparison of different methods for variable selection. Anal Chim Acta 446 : 475 481.
20. Schbeider G., Wrede P. (1998) Artificial neural networks for computer-based molecular dosing. Prog Biophys Mol Biol 70 : 175 222.
21. Coop A. (2005) Biological evaluation of opioid, stimulants, and depressants: I. An overview of the studies performed by the drug evaluation committee of the college on problems of drug dependence (2004). In : Dewey W.L., editor. Problems of Drug Dependence 2004. Washington, DC : National Institute on Drug Abuse Research Monograph Series 185 : 105 130.
22. Coop A. (2006) Biological evaluation of Opioid, stimulants, and depressants: II. An overview of the studies performed by the drug evaluation committee of the college on problems of drug dependence (2005). In : Dewey W.L., editor. Problems of Drug Dependence 2005. Washington, DC : National Institute on Drug Abuse Research Monograph Series 186 : 145 162.
23. Spetea M., Greiner E., Aceto M.D., Harris L.S., Coop A., Schmidhammer H. (2005) Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency. J Med Chem 48 : 5052 5055.
24. Spetea M., Schullner F., Moisa R.C., Berzetei-Gurske I.P., Schraml B., Dorfler C., Aceto M.D., Harris L.S., Coop A., Schmidhammer H. (2004) Synthesis and biological evaluation of 14-alkoxymorphinans. 21.1 Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime. J Med Chem 47 : 3242 3247.
25. Greiner E., Spetea M., Krassnig R., Schullner F., Aceto M.D., Harris L.S., Traynor J.R., Woods J.H., Coop A., Schmidhammer H. (2003) Synthesis and biological evaluation of 14-alkoxymorphinans: 18. 1N-substituted 14-phenylpropoxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships. J Med Chem 46 : 1758 1763.
26. HyperChem TM Release 7.1 for Windows Molecular Modeling System, 1115 NW 4th Street, Gainesville, FL 32601, USA, 2002.
27. Dewar M.J.S., Zeoblish E.G., Healy E.F., Stewart J.J. (1985) Development and use of quantum mechanical molecular models: 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107 : 3902 3909.
28. Baker J. (1993) An algorithm for the location of transition states. J Comput Chem 7 : 385 395.
29. Yamashita S., Furubayashi T., Kataoka M., Sakane T., Sezaki H., Tokuda H. (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10 : 195 204.
30. Todeschini R., Consonni V., Pavan M. (2002) Dragon Software version 2.1-2002. Pisani 13, 20124 Milano, Italy and references there in.
31. Guha R., Jurs P.C. (2005) Determining the validity of a QSAR model - a classification approach. J Chem Inf Model 45 : 65 73.
32. (1999) MATLAB, Version 5.3.1.29215a (R11.1). The MathWorks, Inc.
33. SPSS 13.0 for Windows (2004).
34. (2006) MATLAB, Version 7.2.0.232 (R2006a). The MathWorks, Inc.
35. Topliss J.G., Edwards R.P. (1979) Chance factors in studies of quantitative structure-activity relationships. J Med Chem 22 : 1238 1244.
36. Hoffman R., Minkin V.I., Carpenter B.K. (1997) Ockham's razor and chemistry. HYLE Int J Phil Chem 3 : 3 28.
37. Walker C.A., Owasoyo J.O. (1974) The influence of serotonin, GABA, and DL-dopaon the circadian rhythm in the toxicity of picrotoxin, pentylenetetrazol and phenobarbital in mice. Int J Chronobiol 2 : 125 130.
38. Frederickson R.C., Burgis V., Edwards J.D. (1977) Hyperalgesia induced by naloxone follows diural rhythm in responsivity to painful stimuli. Science 198 : 756 758.
39. Ohdo S., Nakano S., Ogawa N. (1988) Chronopharmacological study of sodium valproate in mice: dose-concentration-response relationship. Jpn J Pharmacol 47 : 11 19.
40. Ohdo S., Koyanagi S., Suyama H., Higuchi S., Aramaki H. (2001) Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 7 : 356 360.
41. Koyanagi S., Ohdo S. (2002) Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. Mol Pharmacol 62 : 1393 1399.
42. Koyanagi S., Kuramoto Y., Nakagawa H., Aramaki H., Ohdo S., Soeda S. (2003) A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 63 : 7277 7283.
43. Yamauchi A., Ichiyama T., Inoue K., Taguchi Y., Matsunaga N., Koyanagi S. (2005) Cell-cycle-dependent pharmacology of methotrexate in HL-60. J Pharmacol Sci 99 : 335 341.
44. Naber D., Wirz-Justice A., Kafka M.S. (1981) Circadian rhythm in rat brain opiate receptor. Neurosci Lett 21 : 45 50.
45. Yoshida M., Ohdo S., Takane H., Tomiyoshi Y., Matsuo A., Yukawa E. (2003) Chronopharmacology of analgesic effect and its tolerance induced by morphine in mice. J Pharmacol Exp Ther 305 : 1200 1205.
46. Consonni V., Todeschini R., Pavan M. (2002) Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors: 1. Theory of the novel 3D molecular descriptors. J Chem Inf Comput Sci 42 : 682 692.